Researchers examining rheumatoid arthritis point to glial cell activity and central nervous system pathways as factors influencing persistent pain, fatigue, and cognitive symptoms alongside joint inflammation.
Investigating Central Nervous System Pathways in Rheumatoid Arthritis
Systemic autoimmune conditions involve more than localized tissue damage. Scientific reviews synthesize preclinical and clinical evidence examining how joint-derived neural inputs and systemic inflammatory signals communicate with the central nervous system. These signals travel through humoral, cellular, neural, neuroendocrine, and neurovascular pathways.
Preclinical studies specifically implicate microglia and astrocytes in neuroinflammatory responses.
Documenting Pain, Fatigue, and Cognitive Burden
Patients frequently report substantial pain, cognitive, affective, and fatigue-related burden that persists even when clinical joint inflammation is low or in remission. Fatigue appears in 44% of early cohorts, with 19% reporting severe fatigue that shows limited improvement over time. This symptom correlates weakly with routine inflammatory markers but strongly with pain, mental health, and overall function.
In a study using painDETECT, neuropathic-like pain features were identified in 22.5% of patients and were independently associated with pain intensity, tender joint count, and education level. These neuropathic-like features showed no independent association with C-reactive protein, erythrocyte sedimentation rates, or the Disease Activity Score in 28 joints. Meanwhile, the prospective multicenter observational VADERA II study of rheumatoid arthritis patients found that 55.4% had at least mild depressive symptoms, yet only 11.7% received antidepressant therapy.
- Persistent pain continuing despite low inflammatory activity or clinical remission in select cohorts
- Nociplastic features such as widespread pain, hyperalgesia, allodynia, and fibromyalgia-related signs
- Cognitive symptoms involving difficulties in memory, attention, and executive function
- Depression and anxiety associated with greater symptom burden and poorer functional outcomes
Evaluating Therapeutic Targeting and Future Research Directions
Parallel developments in therapeutic research explore cellular pathways within joint tissue. Targeting ferroptosis, particularly in pathogenic fibroblast-like synoviocytes, could hold promise for rheumatoid arthritis, according to Burkhard Möller and Jennifer Amsler.
Investigating monoaminergic, kynurenine, fractalkine–CX3CR1, NMDA receptor, and brain-derived neurotrophic factor pathways continues to shape ongoing hypotheses regarding symptom management and drug development.